Sergey Jakimov is a founding partner of LongeVC, a VC fund supporting early-stage biotech and longevity-focused founders who are changing the world.

Serial entrepreneur, having co-founded 3 deep-tech ventures and raised more than $50 million in venture funding for his own ventures and as an entrepreneur in residence. He has worked with several other early-stage companies in the therapeutics space on fundraising, IP protection, and clinical trial strategies, focusing on early treatments in cardiovascular, oncology, and neurodegenerative spaces. Visiting Lecturer to several universities on VC and intellectual property rights, co-authored a master's program in Technology Law for the Riga Graduate School of Law.

Since 2018, he has co-founded medical tech startup Longenesis, a cutting-edge company that unlocks the hidden value of biomedical data and accelerates novel drug treatment & and discovery. In 2021, he co-founded the Longevity Science Foundation, a non-profit organization advancing the field of human longevity by funding research and development of medical technologies to extend the healthy human lifespan. He is also a member of the Longevity Biotechnology Association. Sergey holds a BSc in International Affairs from Rīga Stradiņš University and two MSc in Political Science and Government and Law and Finance from Central European University and Riga Graduate School of Law, respectively. He was named Forbes Latvia's 30 Under 30 in technology and healthcare in 2020.